Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Business - Strategy Off | July 26, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,389 |
Reported balance
After 2026-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-26 · Grant · Acquired 8,450 · Balance 11,389 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 13,113 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,113 |
| Common StockSEC Table I · non-derivative | IndirectLin Family Trust Feb 4, 2024 | 1,740 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,740 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 8,160 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 8,160 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Apr 4, 2022 21:48 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007987 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:43 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017829 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 21:05 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000720 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 4,000 | $6.02 | $24,088.00 |
DisclosureSEC source: 0001567619-21-016470 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,890 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.92 to $6.1099, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:37 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014747 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,890 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013189 · doc1.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013189 · doc1.xml · derivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013189 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:13 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,000 | $6.65 | $13,300.00 |
DisclosureSEC source: 0001567619-21-012486 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,737 Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:11 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011984 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:31 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 31,250 | $4.00 | $125,000.00 |
DisclosureSEC source: 0001567619-20-017589 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,737 F1 · price: This amended Form 4 is being filed to correct the purchase price for the reported transaction. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 31,250 | $2.10 | $65,625.00 |
DisclosureSEC source: 0001567619-20-017572 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,737 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.